New Delhi: vaccine efficacy: With the beginning of the New Year, the countries across the world are preparing to launch massive vaccination campaign against the coronavirus which has affected over 83.9 million people globally so far with more than 1.82 million deaths. In India, the number stands at 1,03,05,788 on Saturday, while the death toll touched 1,49,218.
Most of the countries including India are running for vaccine dry run but have you ever thought that how much is the efficacy of these vaccines in which we are seeing a ray of hope. No doubts, that not even a single vaccine is 100 per cent efficient against the virus. But some of them may deliver a sigh of relief to you. Let’s see how much the efficacy of these vaccines…
Moderna Vaccine or mRNA-1273 is among one of the first vaccines developed to guard against the deadly coronavirus or Covid-19. The vaccine is developed by the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, and Moderna.
According to a study, the vaccine has shown 94.1 per cent efficacy against the virus. The study was published in The New England Journal of Medicine which found that among over 30,000 participants randomised to receive the vaccine or a placebo, 11 in the vaccine group developed symptomatic Covid-19 compared to 185 participants who received the placebo.
The researchers said this demonstrates 94.1 per cent efficacy in preventing symptomatic Covid-19, adding that cases of the severe disease occurred only in participants who received the placebo.
Pfizer and BioNTech Vaccine
The World Health Organization (WHO) has given approval to the Pfizer Biotech vaccine, paving the way for early approval of its import and distribution to countries around the world.
The UK launched the German vaccination campaign on December 8 in collaboration with the United States, Canada and the European Union. According to the studies, this vaccine has an efficacy of 95 per cent.
According to the WHO, the first “emergency confirmation” of the Pfizer / Biotech vaccine was received a year ago after the outbreak of the coronavirus in China.
“Ensuring global access to the Cold 1 vaccine is a very positive step,” said a senior WHO official who is committed to ensuring access to the drug.
Sputnik V vaccine
Sputnik V is the world’s first registered vaccine to be studied based on a well-equipped human adenovirus vector-based platform. It is currently on the World Health Organization’s (WHO) list of 10 candidates who are nearing the start of mass production.
The ongoing post-Sputnik V-registration clinical trial in Russia involved 40,000 volunteers. Clinical trials of Sputnik V have been announced in the USA, India, Venezuela, and Belarus.
The efficacy of the Sputnik V vaccine was confirmed at 91.4 per cent (Source) based on data analysis of the final control point of clinical trials. The efficacy of the Sputnik V vaccine against severe cases of coronavirus is 100 per cent.
RDIF is accelerating the production of Sputnik V jointly with partners and manufacturers. A single dose of the vaccine in the international market will cost less than $10 (Sputnik V is a two-dose vaccine). The lyophilized (dry) form of the vaccine can be kept at a temperature of +2 to +8C.
Requests for more than 1.2 billion doses of the Sputnik V vaccine have come from more than 50 countries. Vaccines for the global market will be supplied by RDIF’s international partners in India, Brazil, China, South Korea, and other countries.
Astra Zeneca Vaccine
AstraZeneca, known in India as CovShield, one of the leading candidates for a vaccine for Covid-19, has shown promising results in the past. Just a few weeks ago, the Serum Institute of India announced that the Oxford Coronavirus vaccine would be available and available to healthcare workers and the elderly by February 2021, while the general public would have access to it by April 2021.
In two different dosing regimens, the AstraZeneca-Oxford Covid-19 vaccine showed the efficacy of 90 per cent and 62 per cent. In participants who received two full doses at least one month apart, vaccine efficacy was 62 per cent, and in participants who received a low dose followed by a full dose, efficacy was 90 per cent.
The AstraZeneca/Oxford vaccine’s efficacy in preventing symptomatic infections was 70.4 per cent, according to interim data, after 30 of 5,807 people who got the two-dose vaccine developed Covid-19, compared with 101 of 5,829 people who got a placebo.